Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than thirty companies, including fifteen which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); Ikaria (acquired by Madison Dearborn, then Mallinckrodt); Kythera Biopharmaceuticals (KYTH), Receptos (RCPT); Aviron (AVIR, acquired by Medimmune-MEDI); Denali Therapeutics; NetBot (acquired by Excite-ATHM); Bluebird Bio (BLUE); R2 Technology (acquired by Hologic-HOLX); XenoPort (XNPT); Caliper Life Sciences (CALP, acquired by PerkinElmer); Trubion Pharmaceuticals (TRBN, acquired by Emergent BioSolutions-EBS); Adolor (ADLR, acquired by Cubist-CBST); deCODE Genetics (acquired by Amgen-AMGN); Array BioPharma (ARRY); Nanosys; GenVec (GNVC); IDUN Pharmaceuticals (acquired by Pfizer-PFE); Genomica (GNOM, acquired by Exelixis-EXEL); Classmates.com (acquired by United Online-UNTD); Nura (acquired by Omeros-OMER); Hua Medicine; VLST; Ensemble Therapeutics; Arivale; Accelerator; Theraclone Sciences; Fate Therapeutics (FATE); NextCODE Health (acquired by WuXi PharmaTech); Bellerophon Therapeutics (BLPH); Syros Pharmaceuticals; Aldedade, Inc. and Everyday Learning Corporation (acquired by Tribune Corp.-TRIB.)
Mr. Nelsen is a director of Agios Pharmaceuticals, Juno Therapeutics, Denali Therapeutics, Sage Therapeutics, Syros Pharmaceuticals, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and as a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.
Bryan joined Venrock as a Kauffman Fellow in 1997. He is based in Venrock’s Palo Alto office and invests broadly across the healthcare industry. Bryan is currently Chairman of the Board of Directors of Achaogen (NASDAQ: AKAO), Castlight Health (NYSE: CSLT), Ironwood Pharmaceuticals (NASDAQ: IRWD) and Kyruus, in addition to serving on the Board of several other private companies. Past investments include Ariosa Diagnostics (acquired by Roche), athenahealth (NASDAQ: ATHN), Ikaria (acquired by Mallinkrodt), Illumina (NASDAQ: ILMN) and Sirna Therapeutics (acquired by Merck). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and has ranked on Forbes’ Midas List seven times, 2008 - 2015.
Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College.
Daniel is the managing partner/senior managing director of Eight Roads Ventures (formerly Fidelity Growth Partners Asia (FGPA)), Fidelity Growth Partners India (FGPI) and Fidelity Growth Partners Japan (FGPJ). Daniel has over 27 years of experience as a venture professional investing in companies throughout Asia, with a focus on Greater China.
Since late 1994, Daniel has been managing director and managing partner of the various entities, responsible for all of F Eight Roads Ventures and private equity activities in the region.
From 1987 to 1994, Daniel was a partner at Arral and Partners (Asia) Limited, an early pioneer venture capital firm based in Hong Kong, associated with having made landmark investments around the Asia region at the early stages of the private equity industry. From 1981 to 1985, Daniel was an analyst in the equity research department of Fidelity Investments in Boston and portfolio management assistant for the Fidelity Magellan Fund. On behalf of Fidelity entities, Daniel is currently on the Board of Directors of a number of portfolio companies including Hua Medicine, DeltaHealth China, Wisers, Innovent Biologics, Adagene, Rugen Therapeutics and Envivo International. Until recently, prior to their successful exits, Daniel held key board positions on several other leading Chinese technology companies, including Alibaba , Asiainfo (NASDAQ: ASIA), BMI, Hurray Holdings (NASDAQ HRAY), Isoftstone (NYSE: ISS) , Asia Renal Care Ltd (acquired by Bumrungrad International) and Wuxi Pharmatech (NYSE: WX). Daniel's role on the Board of these companies spanned a wide range of areas, in each case representing deep involvement in most aspects of their businesses during every key phase of their development. Daniel holds an MBA degree from the Harvard Graduate School of Business and a Bachelor of Arts degree from Dartmouth College.
Dr. Li Chen leads Hua Medicine, a drug discovery company whose mission is to bring clinically differentiated medicines to patients in China and worldwide. Before Dr. Chen founded Hua Medicine, he was the Chief Scientific Officer and Head of Research at Roche R&D Center (China) Ltd. and a member of Roche's Pharma Research Leadership Team.
As a founding Director in this position, Li was responsible for development and implementation of China's drug discovery strategy, creation of the China discovery portfolio, and management of China operations including Biology, Chemistry, Pharmacology, Discovery Technology, Drug Supply and Drug Safety. He developed a "Collaborative Innovation" model through integration of over 100 scientist-based China partnerships with academic institutes, biotech, contract research organizations and clinical development organizations.
During his 18 year pharma career, Li also had several leadership positions at Roche Nutley in New Jersey, including head of combinatorial/high throughput chemistry. He is a co-inventor of two Roche drugs that reached Phase II clinical trials in Asthma and in MED. He also served as a member at Roche's Patent Coordination Committee at Nutley. Li was the President of the Sino-American Pharmaceutical Professionals Association (SAPA) in 2001, and is now a member of the SAPA Board of Directors. He has received numerous honors including the Roche Pharma Olympia Award 2005, Roche D2K Award, and SAPA President's Award. Most recently, he received IBC China Pharma's R&D Award, which recognizes outstanding individuals whose contributions changed the landscape, reputation, and ecosystem for drug R&D in China. He has also received the "Shanghai Leading Talent" Award from the Shanghai government. Li received his Ph.D in Chemistry from Iowa State University. He was formerly a lecturer in Organic Chemistry at East China Normal University, and is currently an adjunct professor of Chemical Biology at Tongji University. He has over 70 publications in numerous peer-reviewed scientific journals and in patent literature.
Jack is a distinguished scientist and serial entrepreneur. He started his career at the Merck Research Laboratories, leaving after 30 years with several drugs to his credit including Trusopt® and Cosopt®, both for the treatment of glaucoma. While at Merck he made important contributions to a wide range of therapeutic areas including, cardiovascular medicine with Aggrastat®, AIDS with Crixivan®, and to peptic ulcer disease where he played a key role in the development of Pepcid®.
Dr. Baldwin was a founder and the Chief Scientific Officer of Pharmacopeia (PCOP), a company specializing in new drug discovery technologies. After 10 years at Pharmacopeia, he founded, and was President and Chief Scientific Officer for Vitae Pharmaceuticals (VTAE) where he applied computational and molecular simulation methods to the discovery of new therapeutic agents. Additionally, he is a co-founder of Hua Medicine, as well as a co-founder and a Board Director of WuXi PharmaTech (WX) in Shanghai, China; he also serves as a Board Director of GlycoMimetics (GLYC).
Dr. Baldwin has published over 125 scientific articles and numerous reviews and has been an invited lector at more than 150 national and international symposiums. He holds over 240 issued United States patents. He has received several awards in recognition of his work including the prestigious Hershberg Award for Important Discoveries in Medically Active Substance and the Outstanding Achievement Awards by the University of Minnesota and the University of Delaware. He was inducted into the Medicinal Chemistry Division Hall of Fame at the 2007 Fall ACS Meeting and received the American Chemical Society, Philadelphia Section Award for Ingenious Contributions to Chemistry in 2008.
Dr. Baldwin received his BS degree in Chemistry from the University of Delaware and his Ph.D. Degree at the University of Minnesota.
Dr. Ge Li is the Founder, Chairman and Chief Executive Officer of WuXi AppTec, a leading R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries with 14,000 employees and 26 R&D sites and offices worldwide.
An entrepreneur, a leader, and a scientist at heart, Dr. Li, named as one of “The 25 Most Influential People in Biopharma in 2015” by FierceBiotech, is working to lead the transformation of biopharma R&D with the conviction that more efficient and cost-effective R&D should be at the core of better medicines for patients.
A pioneer in biopharma R&D service industry in China, Dr. Li founded WuXi in December 2000 with four employees, China’s first modern chemistry hood, and a single 7,000-square-foot chemistry laboratory. During the past 16 years as its Chairman and CEO, Dr. Li has led WuXi’s rapid growth into a global R&D enabling powerhouse with a pioneering open-access platform as the cornerstone. Today, WuXi’s platform is enabling thousands of biopharma and medical device R&D programs from over 3000 collaborators worldwide, and has contributed to many partners’ successes: clinical milestones, successful IPOs, breakthrough designations, and blockbuster drugs that are profoundly improving patients’ lives.
Dr. Li's visionary leadership and achievements have won him numerous prestigious awards and honors, including the “2016 CBA Brilliant Achievement Award”, “2015 SCRIP Executive of the Year Award”, “The 25 Most Influential People in Biopharma in 2015”, “Forbes 25 Notable Chinese-Americans”, “The 60 Most Influential People during 60 Years Pharmaceutical Development in China”, and “Ernst & Young Entrepreneur of the Year China Award”. WuXi has also received many distinguished recognitions, including the “BayHelix Company of the Year” Award (2016), “Asian CRO Company of the Year” Award (2015) , “North American Open-Access R&D Technology Leadership” Award (2015), “Best Company in an Emerging Market” (2014), “Deloitte Technology Fast 500 Asia Pacific” (2004-2009, 6 consecutive years), and “Fast Company 50 Most Innovative Companies” (2009).
Dr. Li earned his bachelor’s degree in Chemistry in 1989 from Peking University and his doctoral degree in Organic Chemistry from Columbia University in 1994. Prior to WuXi, Dr. Li was a founding scientist at Pharmacopeia Inc., a leading combinatorial chemistry platform company.
Dr. Li is a co-author and co-inventor to over 100 scientific publications and issued or pending patents.
Frank is Founder, CEO and CIO of Ally Bridge Group, a global healthcare-focused investment group based in Hong Kong and the US, and of Themes Investment Partners, a China-focused private equity fund. On April 30, 2015, Frank's Ally Bridge Group announced a joint offer with Dr. Ge Li, Chairman, Founder and CEO of Wuxi Pharmatech (NYSE: WX) and co-founder and director of Hua Medicine, to take Wuxi private for USD3.3 billion, the largest healthcare private equity deal in Asia ex-Japan. The landmark Wuxi deal was successfully completed on December 10, 2015 and Frank joins the board of Wuxi as a director.
Frank has expertise in cementing strategic transactions between emerging players and industry leaders, between global companies and Chinese companies, and helping global companies to access the China market while assisting Chinese companies to acquire novel technologies overseas. This unique strategy is exemplified by Frank's successful investment in in Chinese medical devices company Lifetech (HKSE: 1302) and Frank's instrumental role in Lifetech's landmark partnership deal with global medical devices giant Medtronic. Frank and his team have built a portfolio of innovative biopharmaceutical and medtech companies in China, the US and Europe, covering a number of major therapeutic areas ranging from oncology to cardiology, diabetes, ophthalmology, otology, neurology, infectious diseases, orthopedics, urology and dentistry.
Previously, Mr. Yu was Managing Director and Head of China Investments at Och-Ziff Capital Management (OZ), a leading global hedge fund, where he made some of OZ's largest and successful investments. Prior to Och-Ziff, Mr. Yu was a Managing Director at Goldman Sachs in Hong Kong, where he headed several business units and played instrumental roles in some of the most important restructuring, IPO and M&A transactions of leading Chinese companies. Mr. Yu also advised leading global institutions on their China and Asia strategies and transactions. Before Goldman Sachs, Mr. Yu worked at Moody's in New York, and then Credit Suisse in London and Hong Kong.
Dr. Chen is Founder and Managing Partner of Frontline BioVentures. Leon has over 20 years of experience in the Life Sciences industry in China and the U.S. as a venture capitalist, senior management executive, entrepreneur, and scientific inventor.
He is a member of the Expert Review Panel for the Chinese Central Government HR's 1000 Talent Project, and an adviser to BioBAY of Suzhou Industry Park.
As a venture capital investor, his past affiliations include Fidelity Growth Partners-Asia (Partner) and BioVeda China (Managing Partner). Representative Investments include CITIC Pharmaceutical (Director of Board, Acting CFO), Cathay Industrial Biotechnology (Director of Board), Hile Biopharma (Director of Board), Hua Medicine (Shanghai) (Director of Board), Innovent Biologics Ltd (Chairman), Adagene (Director of Board) and MDDF (Director of Board). As a management consultant, his past affiliations include McKinsey & Company (Brussels), Ernst & Young (Palo Alto) and Life Science Strategic Consulting (Managing Partner, San Francisco Bay Area). As a Ph.D. scientist, he worked with Schering Plough (New Jersey), and is a key member of the discovery team of Zytia / Vytorin - a multi-billion drug.
Mr. Chen was a Post-Doc at MIT, Ph.D. (with top honor) from the University of Louvain, Louvain-La-Neuve, B.S. from Peking University. Leon holds 6 issued US Patents, and is co-author of the 14th and 15th Ernst & Young Biotechnology Annual Report.
Raymond is Co-Founder and CEO of Harvest Investments, a leading asset management company in China.
Equipped with rich experience in both investment banking and private equity investments, Raymond plays a critical role in developing and executing investment strategies of the Harvest Investments. Raymond has successfully led a historic mega deal in China, i.e., RMB 15 billion one-time equity investment for a single enterprise, Sino Chemical Commercial Holding Co., Ltd. With Raymond's leadership, Harvest Investments has developed a variety of investment portfolios focusing on healthcare and TMT.
Raymond graduated from Cornell University with Master of Business Administration degree.